**Supplemental Materials**

|  |
| --- |
| **FIGURE 1. Susceptibility reporting for ESBL-producing organisms pre-RB (A) and post-RB (B)\*** |

\*The ESBL phenotype was designated in patient charts with organism identified during pre-RB period (A). After change of breakpoints, no mentioning of ESBL phenotype in patient charts (B).

**FIGURE 2. Patient Inclusion**

**TABLE 1**

|  |  |  |
| --- | --- | --- |
| Panel Name | Neg/Urine Combo 51 (NUC51, Pre-RB) | Neg MIC 46 (Post-RB) |
| Antimicrobial Agent | **µg/mL** | **µg/mL** |
| Amikacin | 16-32 | 4-32 |
| Amoxicillin/K Clavulanate | 8/4-16/8 | 4/2-16/8 |
| Ampicillin | 8-16 | 8-16 |
| Ampicillin/Sulbactam | 8/4-16/8 | 4/2-16/8 |
| Aztreonam | - | 4-16 |
| Cefazolin | 8-16 | 2-16 |
| Cefepime | 4-16 | 2-16 |
| ESβL Screen - Cefotaxime | - | 1 |
| Cefotaxime | 2, 8-32 | 2-32 |
| ESβL Confirmation -  Cefotaxime/K Clavulanate | 0.5/4, 4/4 | - |
| Cefotetan | - | 16-32 |
| Cefpodoxime | - | 2-4 |
| Ceftazidime | 1, 4-16 | 2-16 |
| ESβL Confirmation -  Ceftazidime/K Clavulanate | 0.25/4, 2/4 | - |
| Ceftriaxone | 8-32 | 1-32 |
| Cefuroxime | 4-16 | 4-16 |
| Ciprofloxacin | 1-4 | 1-2 |
| Chloramphenicol | - | 8-16 |
| Doripenem | - | 0.5-2 |
| Ertapenem | 2-4 | 0.5-1 |
| Gentamicin | 4-8 | 1-8 |
| Imipenem | 1-8 | 1-8 |
| Levofloxacin | 2-4 | 1-4 |
| Meropenem | 1-8 | 1-8 |
| Moxifloxacin | 2-4 | 2-4 |
| Nitrofurantoin | 32-64 | 32-64 |
| Piperacillin/Tazobactam | 16, 64 | 8-64 |
| Tetracycline | 4-8 | 4-8 |
| Ticarcillin/K Clavulanate | 16, 64 | 8-64 |
| Tigecycline | - | 1-4 |
| Tobramycin | 4-8 | 1-8 |
| Trimethoprim | - | 8 |
| Trimethoprim/Sulfamethoxazole | 2/38 | 2/38 |